Financial News Feed

Stronger Sell Today ADAP ranks #5021 as SELL CANDIDATE. Weaker Sell
Today ADAP ranks #5021 as SELL CANDIDATE.

ADAP stock Adaptimmune Therapeutics plc

ADAP stock
Adaptimmune Therapeutics plc

Weiss Multi Strategy Advisers LLC decreased its stake in shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 7.1% during the 4th quarter, according to the company in its most recent 13F filing...

Read more

Adaptimmune Ther Ads (ADAP) shares have sparked the interest of some chartists as the Money Flow Index has dropped below 30, potentially heading for key 20 levels. The Money Flow Index is an indicator...

Read more

Tracking the signals for Adaptimmune Ther Ads (ADAP), we have recently spotted the Kaufman Adaptive Moving Average trending down over the past five periods. Traders may be tracking this reading to ide...

Read more

Adaptimmune Therapeutics Plc - American Depositary (NASDAQ:ADAP) showed an increase of 2.63% in shorted shares. It was announced in March by FINRA the 3.73...

Read more

Adaptimmune Therapeutics plc (NasdaqGS:ADAP) has a Piotroski F-Score of 2 at the time of writing. The F-Score may help discover companies with strengthening balance sheets. The score may also be used ...

Read more

The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a huge mover today! The stock decreased 2.57% or $0.1 during the last trading session, reaching $3.79. About 121,652 shares traded. Adaptimmu...

Read more

Adaptimmune Therapeutics Plc – American Depositary (NASDAQ:ADAP) had an increase of 2.63% in short interest. ADAP’s SI was 3.73 million shares in March as released by FINRA. Its up 2.63% from 3.64...

Read more

Research brokerages are projecting Adaptimmune Therapeutics plc (NASDAQ:ADAP) to grow at an accelerated rate over the next 5 years. Wall Street analysts are looking for the company to grow 5.00% over ...

Read more

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One equi...

Read more

Tracking historical levels on shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP), we can see that the stock has seen a price decline over the last 52-week period. In the last year, shares have shed ...

Read more

Major market players are buzzing over Adaptimmune Therapeutics PLC (NASDAQ:ADAP) as their share price hit $3.93 at the end of the most recent trading session. Outstanding shares are common stock autho...

Read more

The stock of Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a huge mover today! The stock decreased 1.89% or $0.09 during the last trading session, reaching $3.88. About 193,143 shares traded. Adaptimm...

Read more

Investors may be interested in viewing the Gross Margin score on shares of Adaptimmune Therapeutics plc (NasdaqGS:ADAP). The name currently has a score of 50.00000. This score is derived from the Gros...

Read more

Active investors are typically interested in the factors that drive stock price movements. Buying an individual stock means that you own a piece of the company. The hope is that the company does very ...

Read more

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) closed at $3.93 after the last trading day, drawing interest from investors and traders. The stock trades on NSDQ in the Medical sector and Medical – Biome...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank